资金与政策在癌症药物研发创新中的作用。 - Suppr

Suppr

超能文献

The role of funding and policies on innovation in cancer drug development.

作者信息

Kanavos P, Sullivan R, Lewison G, Schurer W, Eckhouse S, Vlachopioti Z

机构信息

LSE Health, Department of Social Policy, London School of Economics.

出版信息

Ecancermedicalscience. 2010;4:164. doi: 10.3332/ecancer.2010.164. Epub 2010 Feb 3.

DOI:10.3332/ecancer.2010.164

PMID:22276026

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3234026/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/427b/3234026/f68e55ffc49a/can-4-164f1.jpg

相似文献

The role of funding and policies on innovation in cancer drug development.

Ecancermedicalscience. 2010;4:164. doi: 10.3332/ecancer.2010.164. Epub 2010 Feb 3.

Burden of disease, research funding and innovation in the UK: Do new health technologies reflect research inputs and need?

J Health Serv Res Policy. 2013 Apr;18(1 Suppl):7-13. doi: 10.1177/1355819613476015.

Research on wind power industrial policies' functional mechanism to the quality of enterprise innovation.

Environ Sci Pollut Res Int. 2023 Mar;30(12):34350-34362. doi: 10.1007/s11356-022-24631-z. Epub 2022 Dec 13.

From strategy to action: how top managers' support increases middle managers' commitment to innovation implementation in health care organizations.

Health Care Manage Rev. 2015 Apr-Jun;40(2):159-68. doi: 10.1097/HMR.0000000000000018.

Barriers to Surgical Innovation Research: A Canadian Study on Public Funding Trends.

Surg Innov. 2022 Oct;29(5):646-651. doi: 10.1177/15533506221085469. Epub 2022 Apr 15.

A quasi-natural experimental study on enterprise innovation driven by urban agglomeration policies in China.

Sci Rep. 2023 Jun 26;13(1):10297. doi: 10.1038/s41598-023-37384-7.

How can entrepreneurs experience inform responsible health innovation policies? A longitudinal case study in Canada and Brazil.

Int J Health Plann Manage. 2023 Jul;38(4):967-985. doi: 10.1002/hpm.3636. Epub 2023 Mar 29.

[The French health care funding system for research and innovation in oncology].

Bull Cancer. 2018 Jun;105(6):581-595. doi: 10.1016/j.bulcan.2018.03.006. Epub 2018 May 7.

Does the Low-Carbon City Pilot Policy Promote Green Technology Innovation? Based on Green Patent Data of Chinese A-Share Listed Companies.

Int J Environ Res Public Health. 2021 Apr 1;18(7):3695. doi: 10.3390/ijerph18073695.

Green innovation and green Imports:Links between environmental policies, innovation, and production.

J Environ Manage. 2019 Oct 15;248:109290. doi: 10.1016/j.jenvman.2019.109290. Epub 2019 Jul 27.

引用本文的文献

Clinical Cancer Research in South America and Potential Health Economic Impacts.

Healthcare (Basel). 2023 Jun 15;11(12):1753. doi: 10.3390/healthcare11121753.

Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE.

Clin Pract. 2022 Nov 7;12(6):885-896. doi: 10.3390/clinpract12060093.

Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?

Healthcare (Basel). 2022 Aug 22;10(8):1594. doi: 10.3390/healthcare10081594.

Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases - Is It Time to Update the EU's Orphan Regulation? And if so, What Should be Changed?

Biomed Hub. 2020 Jul 17;5(2):1-11. doi: 10.1159/000509272. eCollection 2020 May-Aug.

Modifying Adaptive Therapy to Enhance Competitive Suppression.

Cancers (Basel). 2020 Nov 28;12(12):3556. doi: 10.3390/cancers12123556.

The political economics of cancer drug discovery and pricing.

Drug Discov Today. 2020 Dec;25(12):2149-2160. doi: 10.1016/j.drudis.2020.09.007. Epub 2020 Sep 11.

The recent landscape of cancer research worldwide: a bibliometric and network analysis.

Oncotarget. 2018 Jul 17;9(55):30474-30484. doi: 10.18632/oncotarget.25730.

Gene function in schistosomes: recent advances toward a cure.

Front Genet. 2015 Apr 15;6:144. doi: 10.3389/fgene.2015.00144. eCollection 2015.

Statistical research on the bioactivity of new marine natural products discovered during the 28 years from 1985 to 2012.

Mar Drugs. 2015 Jan 7;13(1):202-21. doi: 10.3390/md13010202.

Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?

Soc Sci Med. 2015 Apr;131:207-14. doi: 10.1016/j.socscimed.2014.12.007. Epub 2014 Dec 2.

本文引用的文献

Eurocan plus report: feasibility study for coordination of national cancer research activities.

Ecancermedicalscience. 2008;2:84. doi: 10.3332/ecancer.2011.84. Epub 2008 May 20.

Methods for the comparative evaluation of pharmaceuticals.

GMS Health Technol Assess. 2005 Nov 15;1:Doc09.

Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders.

J Am Med Assoc. 1946 Sep 21;132:126-32. doi: 10.1001/jama.1946.02870380008004.

Pharmaceutical R&D: the road to positive returns.

Nat Rev Drug Discov. 2009 Aug;8(8):609-10. doi: 10.1038/nrd2948.

Cancer research funding in Asia.

Mol Oncol. 2007 Sep;1(2):135-7. doi: 10.1016/j.molonc.2007.06.003.

Cancer research funding in Europe.

Mol Oncol. 2007 Sep;1(2):131-4. doi: 10.1016/j.molonc.2007.05.004.

Translational cancer research in Europe.

Mol Oncol. 2007 Jun;1(1):8-10. doi: 10.1016/j.molonc.2007.03.002.

Has the US Cancer Centre model been 'successful'? Lessons for the European cancer community.

Mol Oncol. 2009 Jun;3(3):192-203. doi: 10.1016/j.molonc.2009.03.002. Epub 2009 Apr 1.

'Tackling cancer in the EU: the role of innovation'.

Mol Oncol. 2009 Feb;3(1):18-23. doi: 10.1016/j.molonc.2008.12.003. Epub 2008 Dec 25.

Trends in the global funding and activity of cancer research.

Mol Oncol. 2008 Jun;2(1):20-32. doi: 10.1016/j.molonc.2008.03.007. Epub 2008 Mar 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The role of funding and policies on innovation in cancer drug development.

作者信息

Kanavos P, Sullivan R, Lewison G, Schurer W, Eckhouse S, Vlachopioti Z

机构信息

LSE Health, Department of Social Policy, London School of Economics.

出版信息

Ecancermedicalscience. 2010;4:164. doi: 10.3332/ecancer.2010.164. Epub 2010 Feb 3.

DOI:10.3332/ecancer.2010.164

PMID:22276026

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3234026/

Abstract

摘要

相似文献

The role of funding and policies on innovation in cancer drug development.

Ecancermedicalscience. 2010;4:164. doi: 10.3332/ecancer.2010.164. Epub 2010 Feb 3.

Burden of disease, research funding and innovation in the UK: Do new health technologies reflect research inputs and need?

J Health Serv Res Policy. 2013 Apr;18(1 Suppl):7-13. doi: 10.1177/1355819613476015.

Research on wind power industrial policies' functional mechanism to the quality of enterprise innovation.

Environ Sci Pollut Res Int. 2023 Mar;30(12):34350-34362. doi: 10.1007/s11356-022-24631-z. Epub 2022 Dec 13.

From strategy to action: how top managers' support increases middle managers' commitment to innovation implementation in health care organizations.

Health Care Manage Rev. 2015 Apr-Jun;40(2):159-68. doi: 10.1097/HMR.0000000000000018.

Barriers to Surgical Innovation Research: A Canadian Study on Public Funding Trends.

Surg Innov. 2022 Oct;29(5):646-651. doi: 10.1177/15533506221085469. Epub 2022 Apr 15.

A quasi-natural experimental study on enterprise innovation driven by urban agglomeration policies in China.

Sci Rep. 2023 Jun 26;13(1):10297. doi: 10.1038/s41598-023-37384-7.

How can entrepreneurs experience inform responsible health innovation policies? A longitudinal case study in Canada and Brazil.

Int J Health Plann Manage. 2023 Jul;38(4):967-985. doi: 10.1002/hpm.3636. Epub 2023 Mar 29.

[The French health care funding system for research and innovation in oncology].

Bull Cancer. 2018 Jun;105(6):581-595. doi: 10.1016/j.bulcan.2018.03.006. Epub 2018 May 7.

Does the Low-Carbon City Pilot Policy Promote Green Technology Innovation? Based on Green Patent Data of Chinese A-Share Listed Companies.

Int J Environ Res Public Health. 2021 Apr 1;18(7):3695. doi: 10.3390/ijerph18073695.

Green innovation and green Imports:Links between environmental policies, innovation, and production.

J Environ Manage. 2019 Oct 15;248:109290. doi: 10.1016/j.jenvman.2019.109290. Epub 2019 Jul 27.

引用本文的文献

Clinical Cancer Research in South America and Potential Health Economic Impacts.

Healthcare (Basel). 2023 Jun 15;11(12):1753. doi: 10.3390/healthcare11121753.

Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE.

Clin Pract. 2022 Nov 7;12(6):885-896. doi: 10.3390/clinpract12060093.

Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?

Healthcare (Basel). 2022 Aug 22;10(8):1594. doi: 10.3390/healthcare10081594.

Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases - Is It Time to Update the EU's Orphan Regulation? And if so, What Should be Changed?

Biomed Hub. 2020 Jul 17;5(2):1-11. doi: 10.1159/000509272. eCollection 2020 May-Aug.

Modifying Adaptive Therapy to Enhance Competitive Suppression.

Cancers (Basel). 2020 Nov 28;12(12):3556. doi: 10.3390/cancers12123556.

The political economics of cancer drug discovery and pricing.

Drug Discov Today. 2020 Dec;25(12):2149-2160. doi: 10.1016/j.drudis.2020.09.007. Epub 2020 Sep 11.

The recent landscape of cancer research worldwide: a bibliometric and network analysis.

Oncotarget. 2018 Jul 17;9(55):30474-30484. doi: 10.18632/oncotarget.25730.

Gene function in schistosomes: recent advances toward a cure.

Front Genet. 2015 Apr 15;6:144. doi: 10.3389/fgene.2015.00144. eCollection 2015.

Statistical research on the bioactivity of new marine natural products discovered during the 28 years from 1985 to 2012.

Mar Drugs. 2015 Jan 7;13(1):202-21. doi: 10.3390/md13010202.

Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?

Soc Sci Med. 2015 Apr;131:207-14. doi: 10.1016/j.socscimed.2014.12.007. Epub 2014 Dec 2.

本文引用的文献

Eurocan plus report: feasibility study for coordination of national cancer research activities.

Ecancermedicalscience. 2008;2:84. doi: 10.3332/ecancer.2011.84. Epub 2008 May 20.

Methods for the comparative evaluation of pharmaceuticals.

GMS Health Technol Assess. 2005 Nov 15;1:Doc09.

J Am Med Assoc. 1946 Sep 21;132:126-32. doi: 10.1001/jama.1946.02870380008004.

Pharmaceutical R&D: the road to positive returns.

Nat Rev Drug Discov. 2009 Aug;8(8):609-10. doi: 10.1038/nrd2948.

Cancer research funding in Asia.

Mol Oncol. 2007 Sep;1(2):135-7. doi: 10.1016/j.molonc.2007.06.003.

Cancer research funding in Europe.

Mol Oncol. 2007 Sep;1(2):131-4. doi: 10.1016/j.molonc.2007.05.004.

Translational cancer research in Europe.

Mol Oncol. 2007 Jun;1(1):8-10. doi: 10.1016/j.molonc.2007.03.002.

Has the US Cancer Centre model been 'successful'? Lessons for the European cancer community.

Mol Oncol. 2009 Jun;3(3):192-203. doi: 10.1016/j.molonc.2009.03.002. Epub 2009 Apr 1.

'Tackling cancer in the EU: the role of innovation'.

Mol Oncol. 2009 Feb;3(1):18-23. doi: 10.1016/j.molonc.2008.12.003. Epub 2008 Dec 25.

Trends in the global funding and activity of cancer research.

Mol Oncol. 2008 Jun;2(1):20-32. doi: 10.1016/j.molonc.2008.03.007. Epub 2008 Mar 27.